Examining COVID-19 risks in MS

A large community-based study – believed to be the largest performed worldwide – has provided new data on COVID-19 risks in people with MS.

At MSVirtual2020, Dr Afagh Garjani from the Division of Clinical Neuroscience at the University of Nottingham, UK, presented preliminary findings of a COVID-19 study utilizing the United Kingdom MS Register (UKMSR).

Participants in the UKMSR were asked to join the COVID-19 study on 17 March 2020, just before lockdown was imposed in the UK. Social media was also used to advertise the study. Surveys were completed at initiation into the study and every 2 weeks afterwards.

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.